Oncotarget

Comprehensive Genomic Testing Reveals Treatment Targets in 90% of Advanced Solid Tumors

Jul 29, 2025
Recent groundbreaking research has uncovered genetic alterations in over 90% of advanced solid tumors, offering new hope for personalized cancer treatments. The analysis of 10,000 tumor samples revealed that nearly a third showed mutations tied to existing drugs. Notably, many critical mutations were detected at low levels, often overlooked by simpler tests. The findings emphasize the vital role of comprehensive genomic profiling in expanding treatment options and improving patient care in various cancer types.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

90% Tumors Have Treatable Mutations

  • More than 90% of advanced solid tumors have genetic changes guiding treatment.
  • This highlights the vital impact of large-scale DNA and RNA tumor testing on patient care.
INSIGHT

Genetic Profiling Expands Treatment Options

  • Nearly a third of patients had mutations matching FDA-approved drugs for their cancer.
  • Another third had alterations linked to drugs approved for other cancers, expanding treatment possibilities.
INSIGHT

Sensitive Tests Reveal Rare Mutations

  • Many key mutations occur at very low levels missed by simpler tests.
  • Broader, sensitive testing found rare mutations and gene fusions crucial for targeted therapies.
Get the Snipd Podcast app to discover more snips from this episode
Get the app